# Evaluation of the Safety of Relaxin in Preeclampsia

> **NCT00333307** · PHASE1 · SUSPENDED · sponsor: **Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies** · enrollment: 18 (estimated)

## Conditions studied

- Pre-Eclampsia

## Interventions

- **DRUG:** recombinant human relaxin

## Key facts

- **NCT ID:** NCT00333307
- **Lead sponsor:** Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2006-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2010-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00333307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00333307, "Evaluation of the Safety of Relaxin in Preeclampsia". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00333307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*